Treat-To-Target Trial of Continuous Subcutaneous , sensor-augmented insulin-pump therapy in new-onset diabetes after transplantation (SAPT-NODAT): Efficacy and Safety of an Intensive Insulin Protocol in Renal Transplant Recipients Receiving a Tacrolimus-based Immunosuppression

Trial Profile

Treat-To-Target Trial of Continuous Subcutaneous , sensor-augmented insulin-pump therapy in new-onset diabetes after transplantation (SAPT-NODAT): Efficacy and Safety of an Intensive Insulin Protocol in Renal Transplant Recipients Receiving a Tacrolimus-based Immunosuppression

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 15 Feb 2016

At a glance

  • Drugs Insulin lispro (Primary) ; Insulin suspension isophane
  • Indications Diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms SAPT-NODAT
  • Most Recent Events

    • 15 Feb 2016 Last checked against ClinicalTrials.gov record.
    • 12 Jan 2016 Planned End Date changed from 1 Aug 2015 to 1 Dec 2017 as reported by ClinicalTrials.gov.
    • 12 Jan 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top